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Transgenic macaques would allow to study brain function and diseases. We report that an engineered
adeno-associated virus serotype 9 variant (scAAV9) injected intravenously in newborn rhesus macaques
resultsinefficient,exclusively-neuronalandwidespreadtransductionofthebrain.Thepresentdatapavethe
way to large-scale genetic modelling of brain diseases in the rhesus macaque.
T
heinitialadvancementsintransgenictechnologyhaveledtothegenerationofthefirsttransgenicmonkeyin
2001
1 and a transgenic monkey model of Huntington’s disease in 2008
2. These breakthroughs have opened
the door to genetic manipulation in nonhuman primates but the technical difficulties have prevented this
long awaited technological advancement for the study of brain function to be further developed
3. The recent
developmentoftheviral-mediateddeliveryofgeneshasledtotheidentification ofvirusescapableoftransducing
developing cells and neurons
4–5. Adeno-associated virus (AAV) vectors can mediate long-term stable transduc-
tion in various target tissues. Among those, AAV serotype 9 (AAV9) vectors possess unique characteristics with
notablyastrikingabilitytocrossthebloodbrainbarrier
5.Afterintraparenchymalinjection,AAV9ismorereadily
transported within the brain compared with other AAV serotypes
6. Given the unique properties of AAV9
6, this
serotypewastestedfordeliveringgenestothecentralnervoussystemafterintravenousinjectioninmanyspecies.
When i.v. injected in adult mice, transduction occurs predominantly in astrocytes in both spinal cord and brain.
However, when injected to neonate mice or newborn monkeys, a single intravascular AAV9 injection led to
extensive transduction (60%) indorsalrootganglia, motorneuronsandinneuronsinmost micebrainregions
4,7.
However,notasinglestudydescribedpreciselythebraintropismofAAV9vectorsadministratedintravenouslyin
non-human primates. AAV9 therapy has recently lead to proof-of-concept preclinical rescues in mouse models
(i) of spinal muscular atrophy disease
8–9 and (ii) of a lysosomal storage disorder
10. Ability to transfect brain
decreases over time, being high at P1 and decreasing dramatically by P10 already
8 suggesting a developmental
period in which AAV9 transfection has maximal efficacy.
Wehereinvestigated iftransduction inthebraincellscanbeachievedusing anengineered AAV9vectorinthe
rhesusmacaque(macacamulatta),thespeciesofchoiceinneuroscienceingeneralandinbiologicalpsychiatryin
particular.
Results
GFP expression was found in all analyzed regions, including the cortex, striatum, globus pallidus, thalamus,
midbrain,hippocampusandcerebellum(Fig.1B–J).GFP-positivecellsweremorenumerousinregionsknownto
undergo profound post-natal maturation, such as cortex, hippocampus and Purkinje cells in the cerebellum
(Fig.2A).AquantitativeunbiasedstereologicalevaluationofthenumberofGFP-transducedcellconfirmedthese
observations (Fig. 2B). Even the newborn monkey injected with the lowest viral titer exhibited an efficient
neuronal transduction (Fig. 2B). Posited tropism towards neurons among brain cells was confirmed using triple
staining for NeuN to label neurons, DAPI to label cell nuclei, and anti-GFP antibodies to label transduced-cells.
All GFP-positive cells were NeuN-positive and no GFP-positive glial cell was observed, thereby validating the
neuronal specificity of transduction in macaques injected at post-natal day 1 (Fig. 2C). Finally, to evaluate
distribution to other organs, sections of the liver, the heart, the muscles, the lungs and the kidneys were analyzed
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SCIENTIFIC REPORTS | 2 : 253 | DOI: 10.1038/srep00253 1Figure 1 | Neuronal cell-type specificity and distribution resulting from AAV9 injections at day 1 post-natal. (A) Rostro-caudal representation of
observedsectionsafterintravenousinjectionofAAV9-CMVie-GFP.Colorcoderelateshighlightedareastocolorframes.(B–D)ExtensiveGFPexpression
within cortical neurons was observed (B), including layer II/III pyramidal cell (inset: cortical spiny stellate cell are star-shaped) (C) and layer IV spiny
stellatecell(D).Neuronswereeasilydetectedinthestriatum(left:mediumspinyneurons;right:smallstriatalneurons)(E),globuspallidus(F),thalamus
(G), substantia nigra (H), hippocampus (I) and cerebellum (J). Scale bars, 100mm (B); 20mm (C–J).
Figure 2 | Broad transduction of the nervous system and peripheral organs resulting from AAV9 injections at day 1 post-natal. (A) Rostro-caudal
representation of GFP-transduced neurons after intravenous injection of AAV9-CMVie-GFP. Red dots relate GFP-positive cells. (B) Quantitative
analysis of GFP-positive cells in all analyzed regions, including the cortex, caudate, putamen, globus pallidus internal and external, subthalamic nucleus
and substantia nigra in four newborn monkeys. (C) To confirm transduction of neurons, sections of cortex from newborn injected monkeys were
immunofluorescently labeled with anti-GFP antibody (green), neuron-specific NeuN antibody (red). Merging of the signals produced colocalization,
thus confirming neuronal transduction. (D) Representative images from different organs from C4 monkey (Top left: heart; Top right: liver; Bottom Left:
lung; Bottom right: kidney). Scale bars, 2000 mm (A); 20 mm (C); 80 mm (D); 20 mm (inset D).
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resulted in few GFP-positive cells within heart, liver, lungs and kid-
neys (Fig. 2D) while no GFP signal was detected in the muscles.
Discussion
Althogether, our results show that intravenous delivery of AAV9-
GFP at a dose range of 10
12-10
14 genome copies in one day-old
rhesus macaque results in widespread neuronal targeting with the
maximum transduction efficiency at a viral titer of 10
12 vg/ml.
Transduction of neurons was observed in most regions of the
brain with some heterogeneity, the post-nataly developing struc-
tures like the cortex and hippocampus being more transfected
than deep brain structures such as the midbrain. Although
AAV9 appears a robust viral vector for gene transfer to the brain,
it would provide a promising research tool for delivering genes in
nonhuman primate only if we could reach all structures with
comparable efficiency, the specificity of expression being driven
by structure-specific promoters (i.e. tyrosine hydroxylase for
dopaminergic neurons, parvalbumin for GABAergic interneurons,
etc.). Recent developments of in utero gene delivery technologies
has clearly demonstrated that a near total transfection of neurons
is possible at embryonic stages compatible with the development
of the targeted area
11–12 and such route needs to be now consid-
ered for non-human primates. Additionally, other viral engineer-
ing approaches can be used to further enhance the transduction
capabilities of AAV in this context
13–14. The present data thus
pave the way to the genetic modeling of brain diseases in the
rhesus macaque by targeting mutant gene with tissue-specific
gene expression, offering unique opportunities for modeling
human disease onset, progression and for validating therapeutic
solutions.
Methods
Animals were housed in social cages with their mothers under controlled conditions
of humidity, temperature, and light (12-h light/12-h dark cycle, lights on at 8.00 am);
foodandwaterwereavailableadlibitum.Experimentswerecarriedoutinaccordance
with European Communities Council Directive of 3 June 2010 (2010/6106/EU) for
care oflaboratoryanimals in an AAALAC-accredited facility following acceptance of
study design by the Institute of Lab Animal Science (Chinese Academy of Science,
Beijing, China) IACUC. One day-old male rhesus macaques received intravenous
injections of an AAV9 vector that expresses green fluorescent protein (GFP) under
the control of cytomegalovirus immediate early synapsin intron promoter (AAV9-
CMVie-GFP). Four newborn male monkeys (C1 to C4) were injected with 1 ml with
4 different AAV9 viral titers (C1: 4.00310
14 vg/ml [1.33310
12 particles/g of body
weight]; C2: 9.61310
13 vg/ml [3.2310
11 particles/g of body weight];
C3: 2.65310
14 vg/ml [8.83310
11 particles/g of body weight]; C4: 2.85310
12 vg/ml
[9.5310
9 particles/g of body weight]). Animals were longitudinally followed and
euthanized 2 months post-injection
15. GFP immunohistochemistry was performed
along the rostro-caudal axis of the brain serially cut on a cryostat (50mm-thick;
Fig. 1A)
15. Double immunostaining procedure against GFP and NeuN were per-
formed sequentially. Briefly, 50mm free floating sections were first incubated in a
mouse NeuN antibody (Millipore, MAB377) diluted to 1/500 in PBS-BSA (1/50)-
Triton 0.3% O/N at room temperature (RT). After several washes, NeuN signal was
revealed by incubating a goat anti-mouse antibody conjugated to Alexa568
(Invitrogen, A11004) for 1 hr at RT. Sections were then incubated with rabbit anti-
GFPantibody(Invitrogen,A11122)dilutedto1/1000inPBS-BSA(1/50)-Triton0.3%
for 2 hr at 37uC, washed with PBS and revealed with donkey anti-rabbit antibody
conjugated to Alexa 488 (Invitrogen, A21206) for 1 hr at RT. DAPI staining was
performed using Hoechst dye (Invitrogen, H3569) at 6 mg/mL in PBS for 2 min.
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